Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA

To facilitate the early gastric cancer diagnosis, an assay based on assessing large-scale methylation and fragmentation profiles of the plasma cell free (cfDNA) will be developed and validated.

Inclusion Criteria:Complete clinical info;Patients self-agree to join the study and with signed patient consent and good compliance.The specific inclusion criteria for subjects to be included in the malignant group:According to the definition of AJCC's 8th Edition Cancer Staging Manual, patients with gastric adenocarcinoma confirmed by histopathology and with pathological stages of stage I-IV, including patients with esophageal gastric junction adenocarcinoma (EGJ);Has not previously received any local or systematic anti-tumor treatment.Exclusion Criteria:Diagnosed previously with any kind of malignant tumor;Have received total or partial gastrectomy;Have received bone marrow or organ transplantation;Have received blood transfusion in the past 6 months;Incomplete clinical info or unqualified to participate in the study.